FDA approves novel gene therapy delivery platform for a rare retinal disorder
Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative diseases in other parts of the body
A department adrift from its own “Gold” standards
Phantom citations, misinformation, and imbalance in HHS communications
HHS explains new vaccine recommendations: Is this the “gold standard science” we were promised?
FAQ sent to Congress looks more like fake gold
Rethinking Medications: Truth, Power, and the Drugs You Take
A critical appraisal of the state of the prescription medications in the United States
The tragic termination of the Diabetes Prevention Program Outcomes Study
An invaluable resource is being starved to death with no scientific or ethical justification
The use of placebo controls in clinical trials
Why the value of placebo controls is not an affirmation of a powerful placebo effect
Indiscriminate, Cruel, and Wasteful: Abandoning USAID clinical trials
The chaos and cruelty of its abrupt deconstruction are self-evident and already demonstrable
Botulinum Toxin: A tale of medicine, beauty, and danger
When used responsibly botulinum toxin is very safe, but patients should be especially vigilant about cosmetic treatments done outside a medical setting.
Pegcetacoplan (Syfovre™) for macular degeneration: an update
SBM's guest contributor and ophthalmologist, Dr. David Weinberg, provides an update on the phase 3 trials of pegcetacoplan for macular degeneration. The results are still disappointing.


We are not antivaccine, we are pro unattainable vaccine
When it comes to vaccines: “If it exists we resist.”